TY - CHAP M1 - Book, Section TI - Drug-Coated Balloon Technologies: Technical Features and Clinical Applications A1 - Granada, Juan F. A1 - Cheng, Yanping A1 - Scheller, Bruno A2 - Samady, Habib A2 - Fearon, William F. A2 - Yeung, Alan C. A2 - King III, Spencer B. Y1 - 2017 N1 - T2 - Interventional Cardiology, 2e AB - The concept of delivering antiproliferative drugs via balloon angioplasty has been around for several decades. However, the specific idea of developing a drug-coated balloon (DCB) system originated from the seminal work of professor Ulrich Speck in the use of contrast agents as carriers of antiproliferative drugs.1 At the early stages of his research, it was found that paclitaxel solubility was significantly increased when mixed when contrast agents. Experimental data showed that a repeated intracoronary bolus injection of a taxane-iopromide formulation resulted in significant reduction of neointimal proliferation in the porcine model of restenosis.2,3 In 2001, the concept of mixing iopromide with paclitaxel in a form of a balloon coating was reduced to practice and validated at the experimental level.4 This original DCB formulation was then clinically validated in small randomized controlled studies in the coronary in-stent restenosis5 and de novo superficial femoral artery stenosis settings.6,7 Stimulated by these early clinical results, several DCB programs were started following a similar technologic approach of using hydrophilic carriers as a method to transport paclitaxel into the vessel wall after balloon dilatation. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesscardiology.mhmedical.com/content.aspx?aid=1146598805 ER -